EMEA-002721-PIP04-23 - paediatric investigation plan

tiragolumab

Key facts

• Active substance:
  tiragolumab
• Therapeutic area:
  Oncology
• Decision number:
  P/0405/2023
• PIP number:
  EMEA-002721-PIP04-23
• Pharmaceutical form(s):
  Concentrate for solution for infusion
• Condition(s) / indication(s):
  Treatment of hepatocellular carcinoma
• Route(s) of administration:
  Intravenous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  27/10/2023
• Compliance check done:
  No

Decision

P/0405/2023 : EMA decision of 27 October 2023 on the granting of a product specific waiver for tiragolumab (EMEA-002721-PIP04-23)

Adopted Reference Number: EMA/429200/2023